{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-26-000040","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2026-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.370878+00:00","generated_at":"2026-05-16T05:01:33.538514+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"GRI Bio reiterates FY2025 results: $8.2M cash, $12M loss; raises $6.5M, runway into Q1 2027","bullets":["Cash and cash equivalents of $8.2M at Dec 31, 2025; raised additional $6.5M in Jan 2026 via ATM offering.","Net loss for FY2025 was $12M; R&D expenses increased to $6.8M from $3.8M year-over-year.","Cash runway expected to fund planned operations into the first quarter of 2027.","Positive Phase 2a data for GRI-0621 in idiopathic pulmonary fibrosis reinforces clinical proof-of-concept.","Advancing GRI-0803 for autoimmune indications through IND-enabling studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-26-000040","json":"https://secwatch.observer/filing/0001824293-26-000040.json","markdown":"https://secwatch.observer/filing/0001824293-26-000040.md","text":"https://secwatch.observer/filing/0001824293-26-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429326000040/0001824293-26-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429326000040/val-20260204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:01:33.538514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}